[IPO Spotlight] Vuno, Medical Artificial Intelligence (AI) Company

[Asia Economy Reporter Hyungsoo Park] Founded in 2014, VUNO is a leading medical artificial intelligence (AI) company that owns a self-developed deep learning engine (VONU Net). Last June, VUNO received European CE certification for five VUNO Med Solution products. VUNO Med is a medical AI solution used for disease prognosis and prediction, quantification, diagnostic assistance, and medical process improvement. It can be utilized to shorten analysis time and reduce misdiagnosis rates.

VUNO's products are broadly categorized into four areas: medical imaging, which interprets X-rays, CT scans, etc.; pathology, which interprets digital scanners and microscope images; biosignal, which analyzes vital signs to predict risk levels; and medical voice, which improves medical staff efficiency through automatic speech recognition.

VUNO has sold its medical AI solutions to over 200 medical institutions, establishing references in clinical settings.

Researcher Kyuri Kim from Shinhan Financial Investment explained, "The global AI healthcare market size is expected to reach $11.5 billion in 2023, growing at an average annual rate of about 45% over five years since 2018. Countries are providing policy support by easing regulations and issuing guidelines."

VUNO's initial public offering (IPO) price range is set between 15,000 and 19,500 KRW per share, with 1.8 million shares to be offered. The expected amount to be raised is between 27 billion and 35.1 billion KRW. Subscription will take place over two days from the 16th to the 17th, and the company will be listed on the KOSDAQ market on the 26th.

The funds raised will be used for facility investment (2.155 billion KRW), operating expenses (13.162 billion KRW), research and development (4.964 billion KRW), and overseas expansion (6.373 billion KRW).